Q3 2023 Results - Reimagining Medicine

Company overview Innovation: Pipeline overview Financial review Financial performance Conclusions Appendix Innovation: Clinical trials Expected currency impact for full year 2023 and 2024 References Abbreviations Currency impact vs. PY %pts, assuming late-October exchange rates prevail in 2023 and 2024 -2 FX impact on Net sales 0 I FX impact on Core operating income FINANCIAL PROFILE -1 to -2 -2-1 to -2 -3 -4 I -4 -6 -6 -6 -8 I Q1 Q2 Q3 Q4 FY¦ FY Q1 Q2 Q3 Q4 FY 2023 2024 2023 FY I 2024 Actual Simulation 40 Investor Relations | Q3 2023 Results NOVARTIS | Reimagining Medicine

View entire presentation